List of Excipients in Branded Drug PSEUDOEPHEDRINE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing PSEUDOEPHEDRINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Walgreen Company	pseudoephedrine hydrochloride	0363-0204	CASTOR OIL
Walgreen Company	pseudoephedrine hydrochloride	0363-0204	CELLULOSE, MICROCRYSTALLINE
Walgreen Company	pseudoephedrine hydrochloride	0363-0204	HYPROMELLOSE
Walgreen Company	pseudoephedrine hydrochloride	0363-0204	MAGNESIUM STEARATE
Walgreen Company	pseudoephedrine hydrochloride	0363-0204	SILICON DIOXIDE
Walgreen Company	pseudoephedrine hydrochloride	0363-0204	TITANIUM DIOXIDE
WALGREEN CO	pseudoephedrine hydrochloride	0363-6611	CELLULOSE ACETATE

What are the Most Frequently-Used Excipients in PSEUDOEPHEDRINE HYDROCHLORIDE?

# Of NDCs	Excipient
2	CARNAUBA WAX
23	CASTOR OIL
2	CELLULOSE ACETATE
27	CELLULOSE, MICROCRYSTALLINE
2	COLLOIDAL SILICON DIOXIDE
2	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
2	DIBUTYL SEBACATE

Pseudoephedrine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 29, 2026

Pseudoephedrine hydrochloride is a mature, low-cost oral decongestant with limited composition-of-matter exclusivity and substantial regulatory controls. Commercial value is concentrated in formulation performance, combination products, taste masking, modified release, abuse-deterrent design, supply reliability, and retail-channel execution. Excipient selection affects dissolution, dose uniformity, tablet size, stability, manufacturability, and the ability to differentiate products after core drug patents have expired.

What is the regulatory status of pseudoephedrine hydrochloride?

Pseudoephedrine hydrochloride is an orally active sympathomimetic used for temporary relief of nasal congestion associated with the common cold, sinusitis, allergic rhinitis, and related conditions. In the United States, oral nasal decongestant products are regulated under the FDA over-the-counter monograph framework for internal analgesic, antipyretic, and antirheumatic products, including relevant nasal-decongestant provisions in 21 C.F.R. Part 341.[1]

The principal commercial strengths are:

Product type	Typical pseudoephedrine HCl strength	Release profile	Common use
Immediate-release tablet	30 mg	Rapid release	Daytime congestion relief
Immediate-release tablet or caplet	60 mg	Rapid release	Adult dosing convenience
Extended-release tablet	120 mg	Approximately 12 hours	Twice-daily dosing
Extended-release tablet	240 mg	Approximately 24 hours	Once-daily dosing
Liquid or oral solution	Variable	Rapid release	Pediatric or swallowing-constrained use
Combination product	Variable	Immediate or modified release	Congestion plus pain, allergy, or cough treatment

The active ingredient is also subject to federal retail controls under the Combat Methamphetamine Epidemic Act of 2005. Retail sales are recorded, daily and monthly quantity limits apply, and products are commonly sold from behind the pharmacy counter or through controlled retail systems.[2]

Pseudoephedrine hydrochloride is not a biosimilar product and does not present biologic interchangeability issues. Competitive risk comes primarily from generic OTC products, private-label products, combination products, and alternative decongestants such as phenylephrine.

What excipients are most important in pseudoephedrine hydrochloride tablets?

The best excipient system depends on whether the product is immediate release, extended release, chewable, orally disintegrating, liquid, or a combination product. A conventional immediate-release tablet typically requires a filler, binder, disintegrant, lubricant, and, where needed, a glidant and taste-masking system.

Excipient function	Common options	Commercial purpose	Key risks
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls tablet size and compression	Flow, incompatibility, mouthfeel
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength	Slower disintegration if overused
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes rapid breakup and dissolution	Overcompression, moisture sensitivity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Prevents sticking and improves ejection	Hydrophobic dissolution effects
Glidant	Colloidal silicon dioxide	Improves powder flow	Dusting and blend segregation
Sweetener	Sucralose, aspartame, acesulfame potassium, mannitol	Improves pediatric and chewable acceptability	Stability and labeling constraints
Flavor	Peppermint, citrus, berry, menthol systems	Masks bitterness and odor	Volatility and stability
Film former	Hypromellose, polyvinyl alcohol	Protects tablet and improves swallowability	Coating weight and dissolution
Opacifier or colorant	Titanium dioxide alternatives, iron oxides, approved dyes	Product identification and appearance	Regulatory and market restrictions

Pseudoephedrine hydrochloride is highly water soluble. The main formulation challenge is therefore often not solubility enhancement but controlling disintegration, dissolution, tablet robustness, taste, and dose uniformity. Excessive lubricant levels or prolonged lubrication can slow release. High binder concentrations can produce hard tablets with delayed disintegration.

For direct compression, microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide, and a low-level lubricant can produce a simple platform. Wet granulation may improve content uniformity and flow when the formulation contains a low drug load or when powder segregation is a concern. Dry granulation can reduce water exposure and may be appropriate for moisture-sensitive flavoring or combination formulations.

What excipients are used in extended-release pseudoephedrine products?

Extended-release pseudoephedrine products are the most technically defensible formulation segment. The objective is to release drug over approximately 12 or 24 hours while maintaining acceptable tablet strength and avoiding rapid release under changing gastrointestinal conditions.

Common release-controlling systems include:

1. Hydrophilic matrix polymers such as hydroxypropyl methylcellulose.
2. Hydrophobic matrices using ethylcellulose or lipid excipients.
3. Polymer-coated multiparticulates.
4. Osmotic or semipermeable membrane systems.
5. Coated granules compressed into tablets.

A hydrophilic matrix is usually the lowest-cost approach. The polymer hydrates after ingestion, forms a gel layer, and controls diffusion and erosion. Polymer grade, viscosity, particle size, compression force, and tablet geometry directly affect release.

What formulation risks affect extended-release performance?

Key risks include dose dumping, alcohol-induced release acceleration, food effects, tablet splitting, and variability caused by polymer hydration. A formulation that meets dissolution specifications in standard aqueous media may still perform differently in alcohol-containing media or under fed conditions.

A strong development program should evaluate:

• Dissolution across multiple pH conditions.
• Agitation sensitivity.
• Alcohol robustness.
• Fed and fasted behavior.
• Tablet crushing and chewing.
• Storage under accelerated temperature and humidity.
• Release from intact and damaged tablets.
• Batch-to-batch polymer variability.

Extended-release formulation know-how can create commercial differentiation even when the active ingredient is commoditized. The strongest opportunity is a robust once-daily product with consistent release, low tablet weight, and acceptable manufacturing cost.

What excipient strategy works for pseudoephedrine combination products?

Combination products create more complex excipient requirements because pseudoephedrine may need to release immediately while another active ingredient requires a different release profile.

Examples include combinations with:

• Acetaminophen for congestion and pain or fever.
• Ibuprofen for congestion and pain.
• Loratadine or cetirizine for allergy symptoms.
• Dextromethorphan for cough.
• Guaifenesin for mucus clearance.
• Chlorpheniramine or doxylamine for allergy and nighttime products.

A bilayer tablet can separate incompatible actives or isolate immediate-release and extended-release portions. Multiparticulates can provide more precise release control and may reduce direct contact between actives. Film coating can distinguish release populations, reduce taste, and improve swallowability.

Excipient compatibility must be assessed carefully. Potential problems include:

• Acetaminophen and pseudoephedrine dose balancing in high-strength tablets.
• pH-dependent degradation of co-formulated actives.
• Adsorption of liquid actives onto porous excipients.
• Maillard reactions involving reducing sugars and amine-containing compounds.
• Caking or precipitation in liquid products.
• Color or odor changes during storage.
• Different dissolution requirements for each active ingredient.

A combination product can command greater shelf space and improve consumer convenience, but it also increases labeling, safety, clinical-use, and manufacturing complexity.

How can excipients support abuse-deterrent pseudoephedrine products?

Pseudoephedrine is regulated because it can be diverted for illicit methamphetamine manufacture. Standard excipients cannot eliminate the regulatory obligations imposed by federal retail controls. They can, however, support physical or chemical barriers against tampering.

Potential approaches include:

• Matrix systems that resist crushing and powder recovery.
• Gelling agents that produce a viscous mass when mixed with water.
• Coatings that resist solvent extraction.
• Bitterness systems that discourage ingestion of concentrated extracts.
• Color-change indicators that reveal tampering.
• Packaging with unit-dose or child-resistant features.
• Formulations that limit separation of pseudoephedrine from other ingredients.

These approaches require careful validation. An excipient that reduces extractability may also alter dissolution, create unacceptable gastrointestinal effects, or complicate scale-up. The commercial case is strongest where the product is sold through controlled channels and where manufacturers seek to reduce diversion risk without changing the active ingredient or dose.

What patent protection covers pseudoephedrine hydrochloride products?

Core pseudoephedrine hydrochloride patents are generally legacy rights with limited current commercial significance in the United States. The active ingredient has been marketed for decades, and ordinary immediate-release tablets are generally open to generic and private-label competition.

IP category	Current commercial relevance	Typical protection period
Active ingredient or salt	Low for ordinary pseudoephedrine HCl products	Generally expired or immaterial
Immediate-release tablet	Low unless tied to a specific product platform	Usually expired or weak
Extended-release formulation	Moderate where release architecture is distinctive	Product-specific
Combination product	Moderate for selected compositions and dosing regimens	Product-specific
Manufacturing process	Moderate where it improves yield, purity, or scale	Often limited by design-around options
Packaging and diversion control	Moderate, mainly as a system-level strategy	Jurisdiction and claim dependent
Trademark and trade dress	Commercially important for branded products	Renewable, not patent-based

OTC monograph products usually do not receive the same Orange Book patent-listing treatment as approved prescription products. The FDA Orange Book is focused on approved drug products and listed patents for qualifying applications. A pseudoephedrine product marketed under the OTC monograph pathway generally should not be assumed to have an Orange Book patent estate.[3]

A formulation patent can still matter outside the Orange Book framework. Relevant claims may cover polymer ratios, coated particles, dissolution profiles, abuse-deterrent systems, manufacturing steps, or combinations with other active ingredients. A freedom-to-operate review must examine issued patents, pending applications, continuations, foreign rights, and claim scope rather than relying only on Orange Book data.

When does pseudoephedrine lose exclusivity?

Pseudoephedrine has already lost practical exclusivity for standard immediate-release oral products. Generic entry is not dependent on a future loss-of-exclusivity event for the basic active ingredient.

Commercial exclusivity can still exist through:

• Brand recognition.
• Retailer distribution.
• Private-label contracts.
• Supply agreements.
• Proprietary extended-release technology.
• Combination-product positioning.
• Packaging and controlled-channel execution.
• Manufacturing cost and service reliability.

For a new formulation, exclusivity depends on the patent claims and regulatory pathway. A formulation patent may expire years after launch, but its value depends on whether generic competitors can reproduce the release profile without practicing the claims.

What is the paragraph IV risk for pseudoephedrine products?

Paragraph IV challenges are mainly relevant when a pseudoephedrine product is approved through an abbreviated new drug application or relies on a listed patent associated with an approved extended-release or combination product. Standard OTC monograph products generally do not follow the same paragraph IV pattern as prescription products with Orange Book-listed patents.

Potential challenge targets include:

• Extended-release tablets.
• Controlled-release multiparticulates.
• Combination products with proprietary dosage regimens.
• Abuse-deterrent formulations.
• New delivery systems submitted under an approved application.
• Patents claiming dissolution profiles or polymer architecture.

A generic entrant can also compete without directly challenging a patent by using a non-infringing formulation, launching after patent expiry, or marketing a legally distinct OTC product under the applicable monograph conditions.

What FDA exclusivity applies to pseudoephedrine hydrochloride?

Pseudoephedrine products marketed under the OTC monograph system generally do not receive new-drug exclusivity comparable to a novel prescription product. The commercial pathway is based on compliance with the applicable monograph, labeling requirements, manufacturing controls, and other FDA rules.

A novel pseudoephedrine delivery system or combination may require a different regulatory strategy. If the product falls outside the monograph, the sponsor may need an FDA-approved application. That route can create regulatory exclusivity in limited circumstances, but it also imposes greater development and postmarket obligations.

The main regulatory barriers are:

• Monograph compliance.
• Drug Facts labeling.
• Maximum daily dose and dosing interval.
• Pediatric labeling.
• Drug interaction warnings.
• Manufacturing under current good manufacturing practice.
• Controlled-sale requirements.
• Tamper-resistant and child-resistant packaging where applicable.
• Stability and dissolution specifications.

Which companies compete in pseudoephedrine hydrochloride?

Competition spans branded manufacturers, generic drug companies, consumer-health companies, and retailers. Major commercial brands have included Sudafed products marketed by Kenvue, while generic and private-label products are supplied by companies such as Perrigo, Teva, CVS, Walgreens, Walmart, and other contract manufacturers. Ownership and supply arrangements can change by product and jurisdiction.

The competitive landscape is fragmented because the active ingredient is widely available and consumers often purchase based on price, retailer availability, dose convenience, and brand familiarity. The most defensible commercial positions are:

• National brand recognition.
• Retailer-exclusive private-label supply.
• Reliable year-round manufacturing.
• High-demand seasonal inventory management.
• Once-daily extended-release products.
• Combination products with clear symptom positioning.
• Child-resistant and tamper-evident packaging.
• Low-cost, scalable tablet production.

What commercial opportunities exist for pseudoephedrine excipients?

The highest-value opportunities are not new excipients for the active ingredient itself. They are formulation platforms that solve specific commercial problems.

Low-cost direct-compression platforms

A robust direct-compression system can reduce manufacturing steps and improve gross margin. The target profile is rapid disintegration, consistent dissolution, low friability, and acceptable tablet hardness at high production speed.

Once-daily extended-release tablets

A 240 mg once-daily product can differentiate on convenience. Polymer selection and tablet geometry are central to maintaining a reproducible 24-hour release profile.

Pediatric liquids and chewables

Taste masking, sedimentation control, preservative selection, and dose-measuring accuracy are key. Mannitol, high-intensity sweeteners, flavor systems, suspending agents, and viscosity modifiers can support this segment.

Alcohol-resistant and abuse-deterrent products

A formulation that resists crushing, solvent extraction, or rapid release may support controlled-channel sales and licensing opportunities. The cost-benefit case depends on validation data and retail acceptance.

Combination products

A single tablet addressing congestion plus pain, allergy, cough, or mucus symptoms can increase basket size. Excipient design must preserve the release and stability requirements of each active ingredient.

Sustainable excipient and packaging systems

Reduced coating-solvent use, lower tablet mass, recyclable packaging, and more efficient manufacturing can improve procurement positioning. Sustainability claims must be supported by documented material and lifecycle data.

How strong is the pseudoephedrine patent estate?

The estate is weak for ordinary immediate-release pseudoephedrine hydrochloride tablets and stronger only in selected formulation or delivery-system segments. Patent strength depends on claim breadth, design-around options, remaining term, prosecution history, and whether the claimed release profile can be demonstrated reliably.

A practical diligence ranking is:

Segment	Patent strength	Generic entry risk
Standard immediate-release tablet	Low	High
Standard oral liquid	Low	High
Conventional chewable tablet	Low to moderate	High
Extended-release matrix tablet	Moderate	Moderate
Multiparticulate extended release	Moderate to high	Moderate
Abuse-deterrent system	Moderate to high	Depends on claim design
Combination product	Moderate	Moderate to high
Retail packaging and branding	Non-patent commercial protection	High substitution risk

What generic launch scenarios exist for pseudoephedrine products?

For standard immediate-release products, generic and private-label entry is already established. A new entrant would compete on manufacturing cost, channel access, compliance, supply continuity, and packaging.

For extended-release products, likely launch paths include:

1. A directly substitutable generic using an equivalent release design.
2. A non-infringing formulation with comparable clinical use.
3. An OTC monograph product with different packaging or branding.
4. A private-label arrangement with a national retailer.
5. A combination product that competes for the same congestion indication.

A branded product with a formulation patent faces the greatest risk when competitors can match dissolution performance using a different polymer system or multiparticulate structure.

What litigation and licensing issues affect pseudoephedrine products?

The principal legal issues are likely to involve formulation patents, manufacturing patents, product liability, labeling, controlled-sale compliance, and supply agreements rather than basic active-ingredient patents.

Licensing opportunities may arise for:

• Extended-release polymer platforms.
• Abuse-deterrent technology.
• Pediatric taste-masking systems.
• Combination-product manufacturing.
• Private-label retail supply.
• Contract development and manufacturing.
• High-throughput tablet coating and packaging.

Any transaction should examine patent ownership, field-of-use limits, geographic rights, manufacturing dependencies, regulatory responsibility, change-control provisions, and minimum-volume commitments.

What geographic markets offer the best opportunities?

The United States is commercially attractive because of large OTC demand, established retail infrastructure, and high use of branded and private-label congestion products. It also has unusually strict pseudoephedrine sales controls.

International opportunities depend on local classification, prescription status, dose limits, combination restrictions, and precursor-control rules. A formulation accepted in one market may require different labeling, pack sizes, excipients, or sales channels elsewhere. Geographic freedom to operate must be assessed separately because patent terms, regulatory approvals, and controlled-substance rules vary by country.

Key Takeaways

• Pseudoephedrine hydrochloride is a mature active ingredient with little practical exclusivity for ordinary immediate-release tablets.
• Excipient strategy is most valuable in extended-release, pediatric, chewable, liquid, combination, and abuse-deterrent products.
• Hydrophilic polymer matrices offer the most accessible route to differentiated extended-release products.
• Taste masking and suspension control are central to pediatric and liquid opportunities.
• The FDA OTC monograph pathway limits the value of traditional new-drug exclusivity.
• Orange Book analysis alone is insufficient because many OTC pseudoephedrine products are not supported by conventional Orange Book patent listings.
• Commercial barriers are more important than basic active-ingredient patents for standard products.
• The strongest business opportunities involve formulation platforms, private-label supply, once-daily dosing, controlled-channel packaging, and reliable seasonal manufacturing.

FAQs

Can pseudoephedrine hydrochloride be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating format is technically feasible, but bitterness, moisture sensitivity, tablet friability, dose loading, and mouthfeel are significant development issues. Taste masking may require coated particles, ion-exchange resins, polymer barriers, or intensive sweetener-flavor systems.

Which excipients are preferred for a 12-hour pseudoephedrine tablet?

Hydroxypropyl methylcellulose is a common starting point for a hydrophilic matrix. The final system may also include microcrystalline cellulose, a glidant, a lubricant, and release-modifying polymers. Polymer viscosity and concentration must be optimized against dissolution, tablet size, and manufacturing speed.

Does pseudoephedrine hydrochloride require a prescription in the United States?

No, not generally. It is commonly sold without a prescription, but federal and state controls require identification, sales records, quantity limits, and controlled retail access.

Can a pseudoephedrine formulation receive patent protection after the active ingredient is generic?

Yes. Patent protection may cover a specific release system, polymer ratio, multiparticulate structure, abuse-deterrent architecture, combination, manufacturing method, or dissolution profile. The patent cannot restore exclusivity to the unclaimed conventional product.

Is phenylephrine a direct commercial substitute for pseudoephedrine?

Phenylephrine competes in the oral decongestant market, but it is not an identical technical or regulatory substitute. Differences in perceived efficacy, regulatory review, formulation history, retail positioning, and consumer preference affect competitive performance.

References

1. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

2. U.S. Drug Enforcement Administration. (2024). Combat Methamphetamine Epidemic Act of 2005 and retail sales requirements for pseudoephedrine. https://www.deadiversion.usdoj.gov

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book